LRRK2 Cohort Consortium Publications
A goal of the LRRK2 Cohort Consortium is to bring research groups together early on to share resources and results, speeding collective efforts to move LRRK2 toward practical therapeutic relevance for patients. MJFF catalogs publications and presentations associated with the Consortium here to facilitate such communication.
Researchers accessing resources from the Consortium are required to adhere to the LRRK2 Publications Policy, Data Use Agreement and Biospecimens Use Agreement, which requires that all publications be submitted for administrative review. Email email@example.com to submit a publication for review.
Reports, analyses and subsequent publications on studies identified by MJFF and the LRRK2 Cohort Consortium as fulfilling the primary objectives of the study
Publications from investigators who have accessed either clinical data or biospecimens or both from the LRRK2 Cohort Consortium
|Publication Title||Author(s)||PubMed ID|
|LRRK2 mutations and cancer risk||Rachel Saunders-Pullman, Jan Aasly, Daniela Berg, Susan Bressman, Piu Chan, Karen Marder, Eduardo Tolosa||20818610|
|Increased peripheral inflammation in asymptomatic carriers of the leucine-rich repeat kinase 2 G2019S mutation||Nicolas Dzamko, Dominic B. Rowe, Glenda M. Halliday||26917005|
|Inflammatory profile discriminates clinical endophenotypes in LRRK2-associated PD||Kathrin Brockmann, Claudia Schulte, Nicole Schneiderhan, Anja Apel, Claustre Pont-Sunyer, Dra Dolores Vilas, Javier Ruiz-Martinez, Markus Langkamp, Jean-Christophe Corvol, Florence Cormier, Alice Bernhard, Thomas Gasser, Connie Marras, Birgitt Schüle, Jan O. Aasly, Tatiana Foroud, Jose Felix Marti-Masso, Alexis Brice, Eduardo Tolosa, Daniela Berg, Walter Maetzler|
|Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers||Andrew B. West, Kale B. Fraser, Mark S. Moehle, Roy N. Alcalay|